Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Condition: Chronic Obstructive Pulmonary Disease (COPD) Interventions: Drug: Placebo; Drug: Tozorakimab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition: Hepatocellular Carcinoma (HCC) Interventions: Drug: Durvalumab; Drug: Bevacizumab; Procedure: Transarterial Radioembolization (TARE) Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
Condition: Carcinoma, Non-Small-Cell Lung Intervention: Sponsor: AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition: Hepatocellular Carcinoma (HCC) Interventions: Drug: Durvalumab; Drug: Bevacizumab; Procedure: Transarterial Radioembolization (TARE) Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Condition: Chronic Obstructive Pulmonary Disease (COPD) Interventions: Drug: Placebo; Drug: Tozorakimab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
Condition: Carcinoma, Non-Small-Cell Lung Intervention: Sponsor: AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition: Hepatocellular Carcinoma (HCC) Interventions: Drug: Durvalumab; Drug: Bevacizumab; Procedure: Transarterial Radioembolization (TARE) Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Condition: Chronic Obstructive Pulmonary Disease (COPD) Interventions: Drug: Placebo; Drug: Tozorakimab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
Condition: Carcinoma, Non-Small-Cell Lung Intervention: Sponsor: AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Condition: Chronic Obstructive Pulmonary Disease (COPD) Interventions: Drug: Placebo; Drug: Tozorakimab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
Condition: Carcinoma, Non-Small-Cell Lung Intervention: Sponsor: AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Condition: Chronic Obstructive Pulmonary Disease (COPD) Interventions: Drug: Placebo; Drug: Tozorakimab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
